Highlights Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-08 pm EDT			5-day change	1st Jan Change
131.33 ^USD	-2.04%		-0.24%	+7.00%

May. 08	Gilead Sciences Faces Long-Term Questions on Yeztugo Growth, RBC Capital Markets Says	MT
May. 08	Leerink Partners Adjusts Price Target on Gilead Sciences to $146 From $148	MT

Highlights

May. 07	Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on February 25, 2020.	CI
May. 07	Gilead Sciences Expects Loss This Year on Acquired R&D Expenses	DJ
May. 07	Gilead Sciences Q1 Adjusted Earnings, Revenue Rise; Lowers Full-Year EPS Guidance	MT
May. 07	(GILD) Gilead Sciences Now Expects 2026 Adjusted Loss Per Share Range $1.05-$0.65, vs. FactSet Est for EPS of $8.55	MT
May. 07	Earnings Flash (GILD) Gilead Sciences, Inc. Reports Q1 Revenue $6.96B, vs. FactSet Est of $6.91B	MT
May. 07	Earnings Flash (GILD) Gilead Sciences, Inc. Posts Q1 Adjusted EPS $2.03 per Share	MT
May. 07	Earnings Flash (GILD) Gilead Sciences Posts Q1 Adjusted EPS $2.03 , vs. FactSet Est of $1.91	MT
May. 07	Gilead raises 2026 sales forecast, flags profit hit from acquisitions	RE
May. 07	Earnings Flash (GILD) Gilead Sciences Posts Q1 Revenue $7B, vs. FactSet Est of $6.91B	MT
May. 07	Gilead Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 06	California's highest court leans toward Gilead in considering drugmakers' 'duty to innovate'	RE
May. 06	California's highest court to consider whether drugmakers have 'duty to innovate'	RE
May. 05	Use of Gilead's HIV prevention shot rises, but US insurance gaps remain	RE
May. 01	Big Pharma M&A set for mega year as patent expiries drive deal urgency	RE
Apr. 29	U.S. FDA grants priority review of new drug application for Gilead's once-daily HIV treatment of Bictegravir plus Lenacapavir	RE
Apr. 29	Gilead Sciences, Inc. Receives U.S. FDA Priority Review For Once-Daily HIV Treatment Bictegravir Plus Lenacapavir	CI
Apr. 28	Gilead Sciences completes acquisition of Arcellx ahead of potential commercial launch of Anito-cel	RE
Apr. 28	Gilead Sciences Finalizes $7.8 Billion Acquisition of Arcellx	MT
Apr. 21	UK's British Land lifts earnings forecast as AI firms flock to London campuses	RE
Apr. 17	Gilead's Yeztugo Launch Shows Mix of Perspectives, RBC Says	MT
Apr. 17	Gilead Sciences Says All Required Regulatory Approvals Received for Arcellx Acquisition	MT
Apr. 16	Gilead Sciences' HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says	MT
Apr. 09	Tempus AI Expands Oncology Collaboration With Gilead Sciences	MT
Apr. 08	Gilead to Buy Cancer Biotech Tubulis in $5B Deal	MT
Apr. 08	Gilead Sciences' Tubulis Buy Underscores Shift Beyond HIV, Oppenheimer Says	MT